[Safety and ocular hypotensive effect of a new prostaglandin analogue, S-1033, in normal volunteers].
We conducted a prospective, placebo-controlled, double-masked study to investigate the ocular hypotensive effect and safety of a new prostaglandin analogue, S-1033, in healthy human volunteers. In a single-dose, dose-finding study, where 0.1%, 0.2%, 0.3%, or 0.4% of S-1033 and the vehicle ophthalmic solution was instilled in each one eye of six adult male volunteers and vehicle solution alone in the fellow eye, 0.3% solution showed a significant ocular hypotensive effect at 1, 2, and 8 hours following the instillation and 0.4% solution showed a similar effect at 4 hours after the instillation. The following multiple-dose study, where 0.3% S-1033 solution was instilled twice daily for 8 days in one eye of six volunteers and the vehicle in the follow eye, revealed a significant, continuous intraocular pressure (IOP) reduction. Mild, transient conjunctival hyperemia and slight ocular discomfort developed in some cases, but they were minor. These results indicate that S-1033 has a significant ocular hypotensive effect without substantial adverse effects and the new compound seems to deserve further investigation as a possible anti-glaucoma medication.